After multivariable adjustment using stabilized IPTW, anti-IgE therapy was associated with a significantly lower risk of congestive heart failure (aHR 0.79, 95% CI 0.65–0.95), peripheral artery disease (aHR 0.66, 95% CI 0.51–0.86), and stroke (aHR 0.54, 95% CI 0.36–0.81) compared with patients without biologic therapy. This evidence concerns the gene IGHE and congestive heart failure.